- Home
- SRRK
as 12-18-2024 10:43am EST
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 4.2B | IPO Year: | 2018 |
| Target Price: | $40.43 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.76 - $46.19 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Scholar Rock Holding Corporation (SRRK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | SRRK | 10% Owner | Dec 10 '24 | Sell | $41.65 | 1,600,000 | $66,640,000.00 | 9,250,005 | |
| Invus Public Equities, L.P. | SRRK | 10% Owner | Nov 25 '24 | Sell | $39.34 | 409,433 | $15,757,638.99 | 9,250,005 | |
| Marantz Jing L. | SRRK | CHIEF MEDICAL OFFICER | Nov 22 '24 | Sell | $37.59 | 8,520 | $315,771.05 | 76,130 | |
| Marantz Jing L. | SRRK | CHIEF MEDICAL OFFICER | Nov 11 '24 | Sell | $30.00 | 2,105 | $63,158.42 | 76,130 | |
| Myles Edward H | SRRK | COO & CFO | Oct 8 '24 | Sell | $34.90 | 37,187 | $1,297,658.96 | 161,088 | |
| Myles Edward H | SRRK | COO & CFO | Oct 7 '24 | Sell | $27.19 | 206,240 | $5,477,545.64 | 161,088 | |
| AKKARAJU SRINIVAS | SRRK | Director | Oct 7 '24 | Sell | $30.00 | 1,175,713 | $34,385,672.50 | 5,768,609 | |
| Marantz Jing L. | SRRK | CHIEF MEDICAL OFFICER | Oct 7 '24 | Sell | $27.29 | 109,375 | $2,976,467.65 | 76,130 | |
| Sacco Tracey | SRRK | CHIEF COMMERCIAL OFFICER | Oct 7 '24 | Sell | $25.91 | 30,000 | $768,676.60 | 49,285 |
Latest Scholar Rock Holding Corporation News
SRRK Breaking Stock News: Dive into SRRK Ticker-Specific Updates for Smart Investing
Business Wire
5 days ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Insider Monkey
14 days ago
Why Is Scholar Rock Holding Corporation (SRRK) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
Argus Research
19 days ago
Daily – Vickers Top Buyers & Sellers for 11/29/2024
MT Newswires
23 days ago
Top Midday Gainers
Benzinga
23 days ago
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
MT Newswires
23 days ago
Wedbush Raises Price Target on Scholar Rock to $47 From $40, Maintains Outperform Rating
MT Newswires
23 days ago
Truist Securities Adjusts Price Target on Scholar Rock to $45 From $36, Maintains Buy Rating
BioPharma Dive
23 days ago
Biohaven muscle drug misses goal of SMA study, but advances in obesity
Compare SRRK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SRRK Scholar Rock Holding Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.